Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Bio-Works Technologies AB's Net Margin % or its related term are showing as below:
FRA:1BD'
s Net Margin % Range Over the Past 10 Years
Min: -755.66 Med: -306.65 Max: -3.13
Current: -3.13
FRA:1BD's Net Margin % is ranked worse than 58.28% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 2.2
vs FRA:1BD: -3.13
Bio-Works Technologies AB (FRA:1BD) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bio-Works Technologies AB Net Margin % Related Terms
Bio-Works Technologies AB Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1BD vs ISRG, BDX, MDLN: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, Bio-Works Technologies AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Works Technologies AB Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Works Technologies AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Works Technologies AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Works Technologies AB (FRA:1BD) has a Net Margin % of 15.94% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Bio-Works Technologies AB and its competitors. According to the industry distribution chart, Bio-Works Technologies AB ranks #475 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 58.3%.
Is Bio-Works Technologies AB's Net Margin % too high?
Bio-Works Technologies AB's current Net Margin % is 15.94%. The Medical Devices & Instruments industry median Net Margin % is 2.20. Bio-Works Technologies AB's value of 15.94% is 624.5% above this industry median. Based on the distribution chart, Bio-Works Technologies AB ranks #475 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio-Works Technologies AB has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Works Technologies AB's Net Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio-Works Technologies AB ranks #475 out of 815 companies for Net Margin %. This places Bio-Works Technologies AB in the lower half of its industry. The industry median Net Margin % is 2.20. Bio-Works Technologies AB's value of 15.94% is 624.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.20, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Works Technologies AB's current Net Margin % of 15.94% is 624.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bio-Works Technologies AB and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Works Technologies AB's current Net Margin % is 15.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Works Technologies AB stock overvalued right now?
Based on GuruFocus' analysis, Bio-Works Technologies AB (FRA:1BD) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.32, compared to a current price of €0.29 — trading 10.6% below its estimated fair value. The current Net Margin % is 15.94% and 624.5% above the Medical Devices & Instruments industry median of 2.20. Bio-Works Technologies AB's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bio-Works Technologies AB (FRA:1BD), the current Net Margin % is 15.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Works Technologies AB (FRA:1BD) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Works Technologies AB stock appears to be undervalued.
The current stock price of €0.29 is trading 10.6% below its estimated GF Value™ of €0.32.
GuruFocus considers Bio-Works Technologies AB to be Modestly Undervalued.
Key valuation signals for FRA:1BD:
Net Margin %: 15.94%
GF Value™: €0.32 vs. price of €0.29 (10.6% below fair value)
Industry Position: 624.5% above the Medical Devices & Instruments median (#475 of 815)
No single metric tells the full story. See the FRA:1BD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Works Technologies AB is a Sweden-based life science company which is engaged in designing, developing, manufacturing and supplying products for purification and separation of proteins and other molecules. The product line of the company includes activated resin, immobilized metal-ion affinity chromatography resin, ion exchange chromatography resin, size exclusion chromatography resin and others. The company has also developed affinity chromatography technique, BabyBio Columns, OptiBio glass columns for separating proteins, and protein purification. Bio-Works serves various end users such as academic research laboratories, biopharmaceutical companies, the food and beverage industry and others.
49GF Score
Get the complete analysis for FRA:1BD
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1BD has been successfully added to your 
